[ad_1]
According to the minister, having started independent negotiations, Lithuania would be left out of the joint European Commission acquisition, and the quantity and capacity of the vaccine to be purchased in negotiations with the manufacturers would place Lithuania at the bottom of the queue.
“The contracts we have signed or the commitments to receive large quantities of vaccines from various manufacturers also say that if Lithuania started to negotiate separately, those previous agreements would no longer be valid,” Landsbergis told Lithuanian Radio in an interview on Tuesday.
A strategic issue here is very important for European unity to give us security.
“It is a very important strategic issue here that the European unit will give us the assurance that different manufacturers will have over time with different vaccines, but if we left one, we would basically leave everyone. I would probably suggest not considering this option (traded separately). (…) It should be understood that the size of Lithuania and our opportunities and the need to acquire it today would put us completely at the end of the line when we talk to any manufacturer, ”said G. Landsbergis.
Lithuania buys vaccines against the coronavirus together with other European Union countries from six companies: Moderna, AstraZeneca, Janssen Pharmaceutica NV, Sanofi and GSK, BioNTech and Pfizer and CureVac.
The European Union has so far approved two vaccines against the coronavirus. Last month, the community began vaccinating BionTech and Pfizer, and Moderna approved the vaccine in early January.
According to data from the Department of Statistics, more than 22.5 thousand have been vaccinated in Lithuania so far. people. They are vaccinated with a vaccine developed by BioNTech and Pfizer.
More than 9 million Israel, a population surveyor, said that it plans to have 2 million population will have received two doses of the coronavirus vaccine.
The country’s prime minister, Benjamin Netanyahu, boasts that the vaccination rate is the fastest in the world.
[ad_2]
